Maravai LifeSciences Holdings, Inc. reported fourth quarter 2024 revenue of $56.6 million, marking a 23.7% decrease compared to the same period in the prior year. For the full year 2024, total revenue was $259.2 million, representing a 10.3% decrease over the prior year.
The company recorded a net loss of $(46.1) million for Q4 2024 and a net loss of $(259.6) million for the full year 2024. Adjusted EBITDA was $(1.1) million for the fourth quarter and $35.9 million for the full year.
Maravai provided financial guidance for full-year 2025, projecting total revenue in the range of $185 million to $205 million. This guidance specifically excludes any revenue from high-volume CleanCap for commercialized vaccines, reflecting a strategic shift in revenue expectations.
The Nucleic Acid Production (NAP) segment's Q4 revenue was $38.0 million, down 30.0% year-over-year, while the Biologics Safety Testing (BST) segment's revenue was $18.6 million, down 5.0% year-over-year. For the full year, NAP revenue was $175.0 million (down 14.0%) and BST revenue was $84.2 million (down 0.5%).
The company also confirmed the completion of its multi-year facilities expansion, with Flanders 1 operational for cGMP small molecule manufacturing and Flanders 2 fully operational for Phase 2/3 mRNA service customers. Approximately 50 new products were launched in 2024, and the Annual Report on Form 10-K for 2024 was expected to be filed with the SEC on this date.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.